Advertisement

Search Results

Advertisement



Your search for Matthew S matches 828 pages

Showing 1 - 50


head and neck cancer

Plasma Circulating Tumor HPV DNA for the Detection of Recurrent HPV-Associated Oropharyngeal Cancer

In a study reported in the Journal of Clinical Oncology, Bhishamjit S. Chera, MD, and colleagues found that surveillance for circulating tumor human papillomavirus (HPV) DNA was accurate in identifying disease recurrence in patients with curatively treated HPV-associated oropharyngeal squamous cell ...

multiple myeloma
immunotherapy

Activity of Anti-BCMA BiTE Molecule AMG 420 in Relapsed or Refractory Multiple Myeloma

In a phase I study reported in the Journal of Clinical Oncology, Max S. Topp, MD, and colleagues found the maximum tolerated dose of the investigational anti–B cell maturation antigen (BCMA) bispecific T-cell engager (BiTE) molecule AMG 420 elicited a high response rate in patients with relapsed or ...

breast cancer
immunotherapy

Fam-trastuzumab Deruxtecan-nxki for Previously Treated Unresectable or Metastatic HER2-Positive Breast Cancer

On December 20, 2019, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was granted accelerated approval in the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2...

leukemia

Conditioning Intensity for Allogeneic Transplantation in Patients With AML

In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...

breast cancer
issues in oncology

Are Racial/Ethnic Disparities in Breast Cancer Diagnosis Caused by Health Insurance Coverage?

Lack of insurance coverage is a major cause of delayed breast cancer screening and treatment among minority women, which could lead to a decrease in a patient’s chance of survival. Nearly half of the disparity in later-stage diagnosis between non-Hispanic white women and black, Hispanic, and...

prostate cancer

Olaparib for Previously Treated, Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations

In the phase II TOPARP-B trial—reported by Mateo et al in The Lancet Oncology—investigators found that olaparib showed activity in men with metastatic castration-resistant prostate cancer and DNA damage response (DDR) gene aberrations who had received one or two prior taxane regimens. Study...

lung cancer
immunotherapy

Pembrolizumab in KRAS-Mutant and Wild-Type PD-L1–Positive Nonsquamous NSCLC

In an analysis reported in Annals of Oncology, Roy S. Herbst, MD, PhD, and colleagues found that pembrolizumab was active in both KRAS-mutant and wild-type tumors in a subgroup of patients in the KEYNOTE-042 trial with programmed cell death ligand 1 (PD-L1)-positive nonsquamous non–small cell lung...

lymphoma
immunotherapy

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: KEYNOTE-013 and KEYNOTE-170

Findings in the phase Ib KEYNOTE-013 and phase II KEYNOTE-170 trials, reported in the Journal of Clinical Oncology by Philippe Armand, MD, PhD, of Dana­Farber Cancer Institute, and colleagues, indicate that pembrolizumab is active in relapsed or refractory primary mediastinal large B-cell...

skin cancer

Pembrolizumab in Adjuvant Treatment of Melanoma With Involvement of Lymph Nodes After Complete Resection

In early 2019, pembrolizumab was approved for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.1,2 Supporting Efficacy Data Approval was based on findings in the double-blind EORTC 1325/KEYNOTE-054 trial (ClinicalTrials.gov identifier...

solid tumors
immunotherapy

Nivolumab for Mismatch Repair–Deficient Noncolorectal Cancers

In a study (NCI-MATCH trial subprotocol, arm Z1D) reported in the Journal of Clinical Oncology, Azad et al found that nivolumab was active in mismatch repair–deficient noncolorectal cancers. As stated by the investigators, “The National Cancer Institute Molecular Analysis for Therapy Choice...

hepatobiliary cancer
immunotherapy

Does Second-Line Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Confer a Survival Benefit?

As reported in the Journal of Clinical Oncology by Richard S. Finn, MD, and colleagues, the phase III KEYNOTE-240 trial has shown no statistically significant progression-free or overall survival benefit with pembrolizumab vs placebo in patients with advanced hepatocellular carcinoma who were...

hematologic malignancies

Pretreatment Vitamin D Deficiency in Patients Receiving First-Line Treatment for Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Sven Borchmann, MD, of the German Hodgkin Study Group, University Hospital of Cologne, and colleagues found that pretreatment vitamin D deficiency was associated with significantly poorer progression-free and overall survival in patients...

immunotherapy

Prior Antibiotic Treatment Linked to Poorer Outcomes With Immunotherapy in Patients With Cancer

In a study presented in a brief report in JAMA Oncology,1 David J. Pinato, MD, PhD, of the Imperial College London, and colleagues found that past—but not concurrent—use of broad-spectrum antibiotic therapy was associated with poorer treatment outcomes in patients receiving immune checkpoint...

multiple myeloma

Elotuzumab in Combination Therapy for Previously Treated Multiple Myeloma

In late 2018, elotuzumab was approved for use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.1 Supporting Efficacy Data Approval was based ...

solid tumors

Machine Learning Algorithm for Genome-Derived Prediction of Tumor Type

In a study reported in JAMA Oncology, Penson et al developed a machine learning algorithmic classifier that may be successful in identifying tumor type and origin based on DNA-sequence data obtained at point of care. The study used machine learning to construct and train an algorithmic classifier...

prostate cancer
breast cancer
bladder cancer
pancreatic cancer
kidney cancer
thyroid cancer
gynecologic cancers
immunotherapy

ESMO Congress 2019: Quick Takes From Key Clinical Trials

The ESMO Congress continues to grow as a pivotal platform for research in clinical oncology. At the ESMO Congress 2019, important findings were showcased in more than 2,200 studies, including 93 late-breaking abstracts. The ASCO Post summarized much of that news in separate articles over several...

issues in oncology

Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals

In a study reported in JAMA Oncology,1Jonathan M. Loree, MD, of BC Cancer, Vancouver, British Columbia, Canada, and colleagues found that race and race subgroup analyses were frequently not included in reported trials supporting U.S. Food and Drug Administration (FDA) oncology drug approvals...

hepatobiliary cancer

Postdiagnosis Use of Aspirin in Patients With Biliary Tract Cancer

In a study reported in a research letter in JAMA Oncology, Jackson et al found that postdiagnosis aspirin use was associated with significantly improved overall survival across biliary tract cancer types. Study Details The study involved 2,934 adult patients diagnosed with biliary tract cancer...

pancreatic cancer

Nab-paclitaxel/Gemcitabine/Cisplatin for Previously Untreated, Advanced Pancreatic Cancer

In a phase Ib/II pilot study reported in JAMA Oncology, Jameson et al found that treatment with nab-paclitaxel, gemcitabine, and cisplatin was active in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Study Details In the study, 25 patients were enrolled between...

skin cancer
genomics/genetics

BRAF and MEK Inhibition in Advanced Melanoma With Rare BRAF Mutations

In a study reported in the Journal of Clinical Oncology, Menzer et al found that combined BRAF/MEK inhibitor therapy appeared to be more active than single-inhibitor therapy in advanced melanoma with rare BRAF mutations. Study Details The study involved data from 103 patients with advanced melanoma ...

tecentriq
abraxane

Atezolizumab for PD-L1–Positive Locally Advanced or Metastatic Triple-Negative Breast Cancer

EARLIER THIS YEAR, atezolizumab was granted accelerated approval in combination with nab-paclitaxel in the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express programmed cell death ligand 1 (PD-L1–stained tumor-infiltrating...

kadcyla
paraplatin
taxotere
adriamycin
adrucil
abraxane
ontruzant
herceptin

Biosimilar to Trastuzumab in HER2-Overexpressing Breast, Metastatic Breast, and Metastatic Gastric Cancers

Early in 2019, trastuzumab-dttb was approved as a biosimilar to standard trastuzumab for treatment of HER2-expressing breast cancer in the adjuvant setting, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior...

rozlytrek

Entrectinib for NTRK-Positive Solid Tumors and ROS1-Positive Lung Cancer

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 15, 2019, the oral TRK, ROS1, and ALK kinase...

gastrointestinal cancer

Individual Patient Meta-analysis of Microsatellite Instability as a Prognostic Marker in Resectable Gastric Cancer

In an individual patient data meta-analysis reported in the Journal of Clinical Oncology, Pietrantonio et al found that microsatellite instability (MSI) status was a strong prognostic marker in patients with resectable gastric cancer. The study involved data from 1,556 patients with resectable...

skin cancer
lymphoma
immunotherapy

Pembrolizumab for Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome

In a phase II study reported in the Journal of Clinical Oncology, Khodadoust et al found that pembrolizumab was active in patients with advanced relapsed or refractory mycosis fungoides or Sézary syndrome. In the U.S.-based multicenter trial, 24 patients with advanced mycosis fungoides (n = 9) or...

gynecologic cancers

Neoadjuvant Cisplatin/Gemcitabine Followed by Standard Chemoradiation in Locally Advanced Cervical Cancer

In a Brazilian single-center phase II trial reported in the Journal of Clinical Oncology, da Costa et al found that neoadjuvant cisplatin/gemcitabine followed by standard chemoradiation therapy with cisplatin did not improve outcomes vs chemoradiation therapy alone in locally advanced cervical...

issues in oncology
solid tumors
hematologic malignancies

Flu Vaccine Effectiveness in Patients With Cancer

In a Canadian study reported in the Journal of Clinical Oncology, Blanchette et al found the influenza vaccine was effective among patient with cancer, with greater effectiveness in patients with solid tumors vs those with hematologic malignancies. Study Details The population-based study involved...

solid tumors
immunotherapy

Pamiparib Plus Tislelizumab in Advanced Solid Tumors

In an Australian phase Ia/b trial reported in The Lancet Oncology, Friedlander et al found evidence of activity of the combination of the poly (ADP-ribose) polymerase inhibitor pamiparib and the programmed cell death protein 1 inhibitor tislelizumab in patients with previously treated advanced...

immunotherapy
multiple myeloma

Daratumumab-Based Therapy for Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplantation

On June 27, 2019, daratumumab was approved for use in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.1,2 Supporting Efficacy Data Approval was based on findings in the open-label phase...

colorectal cancer

Physical Activity Level and Outcomes in Metastatic Colorectal Cancer

A prospective cohort study within the phase III Cancer and Leukemia Group B (Alliance)/SWOG 80405 trial found that increased physical activity at baseline was associated with nonsignificant improvement in overall survival, a significant improvement in progression-free survival, and a reduced risk...

lung cancer

Addition of Pemetrexed/Carboplatin to Gefitinib in Advanced EGFR-Mutant NSCLC

In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Noronha et al found that the addition of pemetrexed/carboplatin to gefitinib improved progression-free and overall survival in first-line treatment of advanced EGFR-mutant non–small cell lung cancer...

head and neck cancer

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

pancreatic cancer

Adavosertib Plus Gemcitabine and Radiotherapy in Locally Advanced Pancreatic Cancer

In a phase I dose-escalation trial reported in the Journal of Clinical Oncology, Cuneo et al established the phase II dose of the Wee1 kinase inhibitor adavosertib in combination with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Wee1 inhibition impedes DNA damage response and ...

solid tumors
immunotherapy

T-Cell Receptor Gene Therapy in HPV-Associated Epithelial Cancers

In a first-in-human phase I/II study reported in the Journal of Clinical Oncology, Doran et al found that autologous genetically engineered T cells expressing a T-cell receptor directed against the human papillomavirus (HPV)16 E6 oncoprotein were capable of inducing tumor regression in metastatic,...

lung cancer

Addition of Cediranib to Cisplatin/Pemetrexed in Chemotherapy-Naive Unresectable Malignant Pleural Mesothelioma

In the phase II SWOG S0905 trial reported in the Journal of Clinical Oncology, Tsao et al found that the addition of the epidermal growth factor receptor and platelet-derived growth factor receptor inhibitor cediranib to cisplatin/pemetrexed was associated with limited benefit and greater toxicity...

cns cancers

Response- and Biology-Based Therapy for Pediatric Intermediate-Risk Neuroblastoma

As reported in the Journal of Clinical Oncology by Twist et al, use of reduced therapy for subsets of pediatric patients with intermediate-risk neuroblastoma in the Children’s Oncology Group (COG) study ANBL0531 did not affect the excellent overall survival rates observed in prior COG studies ...

Conquer Cancer Honors Oncology Professionals With Merit Awards at the 2019 ASCO Annual Meeting

Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2019 ASCO Annual Meeting Merit Awards. These distinguished awards support oncology trainees who were first authors on abstracts selected for presentation at the ASCO Annual Meeting. This year, Conquer Cancer...

lung cancer
immunotherapy

Maintenance Bevacizumab, Pemetrexed, or Both in Advanced Nonsquamous NSCLC

In the phase III ECOG-ACRIN 5508 trial, reported in the Journal of Clinical Oncology by Ramalingam et al, maintenance pemetrexed or bevacizumab was associated with no significant improvement in overall survival vs the bevacizumab control group alone, and was associated with greater toxicity in...

breast cancer
cost of care

How Treatment Costs Affect Decisions for Breast Cancer Surgery

In a study reported in the Journal of Oncology Practice, Greenup et al found that cancer treatment costs influenced women’s decisions on breast cancer surgery. Researchers reported many women, even at the highest income levels, said that costs were higher than expected, and that most women...

solid tumors
immunotherapy

Tumor-Associated Antigen Cytotoxic T Cells in Relapsed or Refractory Solid Tumors

In a phase I trial reported in the Journal of Clinical Oncology, Hont et al found that treatment of relapsed or refractory solid tumors with ex vivo expanded autologous multiantigen-associated specific cytotoxic T cells—or, tumor-associated antigen cytotoxic T cells—was safe and showed...

breast cancer

Ten-Year Update on Standard Adjuvant Chemotherapy vs Capecitabine in Older Women With Early Breast Cancer

As reported in the Journal of Clinical Oncology by Muss et al, long-term findings from the phase III CALGB 49907 trial support the finding from the primary analysis—that standard adjuvant chemotherapy improved recurrence-free survival vs capecitabine in women aged 65 years or older with early ...

lung cancer
immunotherapy

Pembrolizumab After Stereotactic Body Radiotherapy in Advanced NSCLC

In a Dutch phase II study reported in JAMA Oncology, Theelen et al found that although use of stereotactic body radiotherapy prior to pembrolizumab increased the objective response rate vs pembrolizumab alone in metastatic non–small cell lung cancer (NSCLC), the difference did not meet study...

ASCO, Conquer Cancer Congratulate 2019 Grant and Award Recipients

Conquer Cancer®, the ASCO Foundation, presented more than $7 million in grants and awards to exceptional oncology researchers at the 2019 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...

gynecologic cancers

Cervicovaginal Microbiome, BRCA1 Mutation Status, and Ovarian Cancer Risk

In a case-control study reported in The Lancet Oncology, Nené et al found that younger women with ovarian cancer or a BRCA1 mutation without cancer were more likely to have cervicovaginal microbiota characterized by a lower (community type O) vs higher (community type L) proportion of...

leukemia

CLARITY: Ibrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia

In the phase II CLARITY trial reported in the Journal of Clinical Oncology, Hillmen et al found that the combination of ibrutinib and venetoclax resulted in high rates of minimal residual disease eradication in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). In the...

lung cancer
gastroesophageal cancer
bladder cancer
gastrointestinal cancer
immunotherapy

Ramucirumab Plus Pembrolizumab in Previously Treated Advanced Gastroesophageal Cancer, NSCLC, and Urothelial Carcinoma

Results from a phase IB trial expansion stage reported in The Lancet Oncology by Herbst et al showed the combination of ramucirumab plus pembrolizumab had manageable toxicity and antitumor activity in previously treated advanced gastroesophageal cancer, non–small cell lung cancer (NSCLC), and ...

skin cancer

Does Size of Surgical Excision Margins for Thick Localized Cutaneous Melanoma Affect Survival Outcomes?

In a nearly 20-year follow-up of a Scandinavian trial reported in The Lancet, Utjés et al found no difference in survival outcomes with 2-cm vs 4-cm surgical excision margins for primary localized cutaneous melanoma with a thickness > 2 mm. The previous report from the trial showed no...

lymphoma
survivorship

Long-Term Health Outcomes After Lymphome Malin de Burkitt Chemotherapy for Pediatric Mature B-Cell Non-Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Ehrhardt et al found that long-term health outcomes were comparable in patients receiving contemporary Lymphome Malin de Burkitt (LMB) vs non-LMB chemotherapy regimens for pediatric mature B-cell non-Hodgkin lymphoma, except for adverse...

leukemia
survivorship

Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-Term Survivors of Childhood ALL

In a study reported in JAMA Oncology, Banerjee et al found that higher cumulative anesthesia exposure and duration of exposure during treatment of childhood acute lymphoblastic leukemia (ALL) may be associated with adverse neurocognitive and abnormal neuroimaging outcomes in long-term survivors....

leukemia

Substitution of Clofarabine for Anthracycline/Etoposide in Induction Therapy for Pediatric Acute Myeloid Leukemia

In the phase III AML08 trial reported in the Journal of Clinical Oncology, Rubnitz et al found that the use of clofarabine instead of an anthracycline and etoposide in the first course of induction therapy may be a feasible strategy in pediatric patients with acute myeloid leukemia. The trial,...

Advertisement

Advertisement



Advertisement